|
|
|
The Business of Biotech returned to San Francisco for the J.P. Morgan Healthcare Conference. We spoke with Marc Salzberg, M.D., CEO and CMO of Airway Therapeutics, about advancing innovative recombinant surfactant protein D for respiratory and inflammatory diseases, now in Phase 2b/3 trials. |
|
|
|
|
|
|
|
|
|